☰

Himanshu Naik, Ph.D. - Publications

Affiliations: 
2007 University of Iowa, Iowa City, IA 
Area:
Pharmacology
Tree Info Similar researchers PubMed Report error

16 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Zhao Y, Versavel M, Tidemann-Miller B, Christmann R, Naik H. Evaluation of the Potential Pharmacokinetic Interactions Between Vixotrigine and an Oral Contraceptive. Clinical Drug Investigation. PMID 32564301 DOI: 10.1007/S40261-020-00931-5  0.32
2020 Hartmann S, Biliouris K, Naik H, Rabah D, Stevenson L, Shen C, Nestorov IA, Lesko LJ, Trame MN. A clinical population pharmacokinetic/pharmacodynamic model for BIIB059, a monoclonal antibody for the treatment of systemic and cutaneous lupus erythematosus. Journal of Pharmacokinetics and Pharmacodynamics. PMID 32335844 DOI: 10.1007/S10928-020-09688-Y  0.348
2019 Dunbar J, Versavel M, Zhao Y, Tate S, Morisset V, Giblin GMP, Palmer J, Tidemann-Miller B, Naik H. Evaluation of the Pharmacokinetic Interaction Between the Voltage- and Use-Dependent Nav1.7 Channel Blocker Vixotrigine and Carbamazepine in Healthy Volunteers. Clinical Pharmacology in Drug Development. PMID 31650711 DOI: 10.1002/Cpdd.739  0.334
2019 Musselli C, Gaudreault F, Naik H, Carroll H, Sharma A, Huang X, Franchimont N. Fri0204 Safety, Tolerability, Pharmacokinetic And Pharmacodynamic Effect Of Biib059, A Monoclonal Antibody Targeting Bdca2 Following Administration Of Subcutaneous Single Doses In Japanese Healthy Volunteers Annals of the Rheumatic Diseases. DOI: 10.1136/Annrheumdis-2019-Eular.8393  0.357
2018 Biliouris K, Nestorov I, Naik H, Dai D, Xiao G, Wang Q, Pellerin A, Rabah D, Lesko LJ, Trame MN. A pre-clinical quantitative model predicts the pharmacokinetics/pharmacodynamics of an anti-BDCA2 monoclonal antibody in humans. Journal of Pharmacokinetics and Pharmacodynamics. PMID 30377889 DOI: 10.1007/S10928-018-9609-6  0.3
2018 Barbey C, Naik H, Musselli C, Christmann R, Stevenson L, Rabah D, Gulati P, Franchimont N. FRI0315 Safety, tolerability, pharmacokinetic and pharmacodynamic effects of biib059, a monoclonal antibody targeting bdca2 following intravenous (IV) and subcutaneous (SC) single or multiple doses administration in healthy volounteers (HV) and subjects with active systemic lupus erythematosus (SLE) Annals of the Rheumatic Diseases. DOI: 10.1136/Annrheumdis-2018-Eular.2619  0.363
2015 Naik H, Chan S, Vakilynejad M, Chen G, Loft H, Mahableshwarkar AR, Areberg J. A Population Pharmacokinetic-Pharmacodynamic Meta-Analysis of Vortioxetine in Patients with Major Depressive Disorder. Basic & Clinical Pharmacology & Toxicology. PMID 26525043 DOI: 10.1111/Bcpt.12513  0.312
2014 Areberg J, Petersen KB, Chen G, Naik H. Population pharmacokinetic meta-analysis of vortioxetine in healthy individuals. Basic & Clinical Pharmacology & Toxicology. 115: 552-9. PMID 24766668 DOI: 10.1111/Bcpt.12256  0.396
2013 Naik H, Tsai MC, Fiedler-Kelly J, Qiu P, Vakilynejad M. A Population Pharmacokinetic and Pharmacodynamic Analysis of Peginesatide in Patients with Chronic Kidney Disease on Dialysis. Plos One. 8: e66422. PMID 23840463 DOI: 10.1371/Journal.Pone.0066422  0.322
2012 Leifke E, Naik H, Wu J, Viswanathan P, Demanno D, Kipnes M, Vakilynejad M. A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes. Clinical Pharmacology and Therapeutics. 92: 29-39. PMID 22669289 DOI: 10.1038/Clpt.2012.43  0.366
2012 Naik H, Vakilynejad M, Wu J, Viswanathan P, Dote N, Higuchi T, Leifke E. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers. Journal of Clinical Pharmacology. 52: 1007-16. PMID 21610201 DOI: 10.1177/0091270011409230  0.393
2012 Naik H, Tsai M, Qiu P, Vakilynejad M. A Population Pharmacokinetic (Pk)- Pharmacodynamic (Pd) Analysis Of Peginesatide India Lysis Patients With Chronic Kidney Disease Kidney Research and Clinical Practice. 31. DOI: 10.1016/J.Krcp.2012.04.496  0.335
2009 Tan B, Naik H, Jang IJ, Yu KS, Kirsch LE, Shin CS, Craft JC, Fleckenstein L. Population pharmacokinetics of artesunate and dihydroartemisinin following single- and multiple-dosing of oral artesunate in healthy subjects. Malaria Journal. 8: 304. PMID 20021657 DOI: 10.1186/1475-2875-8-304  0.569
2007 Naik H, Imming P, Schmidt MS, Murry DJ, Fleckenstein L. Development and validation of a liquid chromatography-mass spectrometry assay for the determination of pyronaridine in human blood for application to clinical pharmacokinetic studies. Journal of Pharmaceutical and Biomedical Analysis. 45: 112-9. PMID 17681448 DOI: 10.1016/J.Jpba.2007.06.018  0.384
2007 Naik H, Wei SY, Schmidt MS, Murry DJ, Fleckenstein L. Development and validation of a liquid chromatography-mass spectrometry assay for the determination of pyronaridine in human urine. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 853: 80-7. PMID 17409032 DOI: 10.1016/J.Jchromb.2007.02.054  0.383
2005 Naik H, Murry DJ, Kirsch LE, Fleckenstein L. Development and validation of a high-performance liquid chromatography-mass spectroscopy assay for determination of artesunate and dihydroartemisinin in human plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 816: 233-42. PMID 15664355 DOI: 10.1016/J.Jchromb.2004.11.042  0.554
Show low-probability matches.